Home

Prospects of complex use of pharmacological neuroprotection and vascular endothelial growth factor inhibitors in patients with macular edema with retinal vein occlusion

Written by Danilova L.P., Egorov V.V., Smoliakova G.P., Povalyaeva D.A., Zhaivoronok N.S., Emanova L.P.

  UDK: 617.736–005.98–02:616.145.154–085.214.2 | DOI: 10.17238/PmJ1609-1175.2019.2.33–37 | Pages: 33–37 | Full text PDF | Open PDF 

Annotation:

Objective: to assess clinical effectiveness of complex use of ‘Lucentis’ and ‘Meldonium’ in the treatment of macular edema caused by retinal vein occlusion.
Methods: 35 patients (35 eyes) with macular edema with retinal vein occlusion were undergone three consecutive “load” intravitreal administrations of 0.5 mg (0.005 mL) of ‘Lucentis’ once a month. In 19 cases, the introduction of Lucentis was supplemented with daily parabulbar injections of 0.5 ml of Meldonium solution for 10 days.
Results: Using Meldonium visual acuity increased by 3.5 times, light sensitivity of the central zone of the retina – 2.1 times and electrical lability – 1.2 times. Visual electric threshold of retina decreased by 1.5 times.
Conclusions: The improvement of functional parameters in the combined treatment is due to the ability of Meldonium to activate the recovery of the chorioretinal microblood in the macula. The results of a clinical study on the reversibility of ischemic and metabolic injuries of the neuroreceptors of the macula in patients with macular edema with retinal vein occlusion allow us to recommend ‘Meldonium’ for the improvement of visual functions after the intravitreal administration of ‘Lucentis’.

Links to authors:

L.P. Danilova1, 2, V.V. Egorov1, 2, G.P. Smoliakova1, 2, D.A. Povalyaeva1, N.S. Zhaivoronok1, L.P. Emanova1
1 Khabarovsk branch of S.N. Fyodorov NMRC “MNTK “Eye Microsurgery” (211 Tikhookeanskaya St. Khabarovsk 680033 Russian Federation),
2 Postgraduate Institute for Public Health Workers (9 Krasnodarskaya St. Khabarovsk 680000 Russian Federation)


1. Astakhov Yu.S., Petrishchev N.N., Tultseva S.N. Retinal vein thrombosis: etiology, pathogenesis, clinic, diagnosis, treatment. St Petersburg: Pavlov First St. Petersburg State Medical University, 2005. 60 p.
2. Budzinskaya M.V., Mazurina N.K., Egorov A.E. [et al.]. The algorithm of treatment patients with retinal vein occlusion. Report 3. Neovascular complications // Annals of Ophthalmology. 2015. No. 6. P. 67–75.
3. Danilova L.P., Egorov V.V., Smoliakova G.P. [et al.]. Efficiency of functional rehabilitation of patients with degenerative myopia complicated by choroidal neovascularization, combined use of Ranibizumab and Retinalamin // Modern technologies in ophthalmology. 2016. No. 2. P. 97–101.
4. Egorov E.A., Astakhov Yu.S., Stavitskaya T.V. Ophthalmopharmacology. Moscow: GEOTAR-Media, 2009. 592 p.
5. Kiseleva T.N. Ocular ischemic syndrome (clinic, diagnosis, treatment): Dissertation abstracts. Moscow, 2001. 32 p.
6. Tultseva S.N., Astakhov Yu.S. Retinal vein occlusion (etiology, pathogenesis, clinic, diagnosis, treatment). St. Petersburg: N-L Publ., 2010. 112 p.
7. Tultseva S.N., Astakhov Yu.S. The role of inflammation in pathogenesis of postthrombotic macular edema. Modern directions of drug treatment // Ophthalmology Journal. 2012. Vol. 5, No. 4. P. 35–44.
8. Schuko A.G., Zlobin I.V., Yurieva T.N. [et al.]. Imbalance of intraocular cytokines at retinal vein occlusion and its relationship with effectiveness of anti-angiogenic therapy // Annals of Ophthalmology. 2015. Vol. 131, No. 2. P. 50–58.
9. Berger A.R., Cruess A.F., Altomare F. [et al.]. Optimal treatment of retinal vein occlusion: Canadian expert consensus // Ophthalmologica. 2015. Vol. 234, No. 1. P. 6–25.
10. Campochiaro P.A., Pearlman S.R., Brown D.M. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study // Ophthalmology. 2014. Vol. 121, No. 1. P. 209–219.
11. Ip M.S., Scott I.U. VanVeldhuisen P.C. [et al.]. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema decondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5 // Arch. Ophthalmol. 2009. Vol. 127, No. 9. P. 1101–1114.
12. Kanski J.J. Retinal venous occlusive disease // Clinical ophthalmology: A systematic approach, 6th ed. Edinburg; London: Butterworth-Heinemann ELSEVIER, 2007. P. 584–590.
13. Karia N. Retinal vein occlusion: pathophysiology and treatment options // Clin. Ophthalmol. 2010. No. 4. P. 809–816.
14. Pearse A.K., Srinivas R.S. Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab // Clin. Ophthalmol. 2011. No. 5. P. 771–781.
15. Wong T.Y., Scott I.U. Clinical practice. Retinal-vein occlusion // N. Engl. J. Med. 2010. Vol. 363, No. 22. P. 2135–2144.

PUBLISHER: "MEDITSYNA DV"

Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.